Literature DB >> 22089058

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.

Natalia Lopez-Andrès1, Patrick Rossignol, Wafae Iraqi, Renaud Fay, Josette Nuée, Stefano Ghio, John G F Cleland, Faiez Zannad, Patrick Lacolley.   

Abstract

AIMS: Circulating biomarkers of collagen turnover reflect extracellular cardiac matrix (ECCM) remodelling. The extent to which the success of cardiac resynchronization therapy (CRT) is influenced by the degree of cardiac fibrosis and whether CRT can influence matrix remodelling has yet to be studied. Our aim was to determine, in patients with heart failure (HF) and cardiac dyssynchrony, whether ECCM biomarkers are influenced by CRT and can predict cardiovascular outcomes and response to CRT. METHODS AND
RESULTS: Serum levels of ECCM biomarkers [galectin-3 (Gal-3), N-terminal propeptides of type I and III procollagens (PINP and PIIINP), type I collagen telopeptide (ICTP), and matrix metalloproteinase 1 (MMP-1)] were measured in 260 patients, in a substudy of CARE-HF, a randomized controlled trial which evaluated the effects of CRT in patients with left ventricular systolic dysfunction and cardiac dyssynchrony. ECCM biomarkers did not change throughout the 18-month follow-up period. In age- and gender-adjusted analyses, Gal-3 and PIIINP were associated with death or HF hospitalization. In a further multivariate model, Gal-3 >30 ng/mL was associated [OR (95% CI):2.98 (1.43-6.22), P = 0.004] with death or HF hospitalization, along with left ventricular end-systolic volume >200 mL [3.42 (OR: 1.65-7.10), P = 0.001]. The outcome death or left ventricular ejection fraction (LVEF) ≤35% was associated with MMP-1 [≤3 ng/mL: 3.04 (1.37-6.71), P = 0.006]. No significant interaction was observed between the tested biomarkers and the treatment group.
CONCLUSIONS: Increased Gal-3 and PIIINP, and low MMP-1 are associated with adverse long-term cardiovascular outcomes but did not predict response to CRT. CRT did not favourably affect serum concentrations of ECCM markers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089058     DOI: 10.1093/eurjhf/hfr151

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  62 in total

Review 1.  Atrial remodeling, fibrosis, and atrial fibrillation.

Authors:  José Jalife; Kuljeet Kaur
Journal:  Trends Cardiovasc Med       Date:  2014-12-31       Impact factor: 6.677

Review 2.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 3.  Immunohistochemical detection of early myocardial infarction: a systematic review.

Authors:  Cristina Mondello; Luigi Cardia; Elvira Ventura-Spagnolo
Journal:  Int J Legal Med       Date:  2016-11-25       Impact factor: 2.686

Review 4.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

5.  Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman
Journal:  Antioxid Redox Signal       Date:  2019-03-29       Impact factor: 8.401

Review 6.  Clinical, laboratory, and pacing predictors of CRT response.

Authors:  Jagdesh Kandala; Robert K Altman; Mi Young Park; Jagmeet P Singh
Journal:  J Cardiovasc Transl Res       Date:  2012-02-24       Impact factor: 4.132

7.  The potential role of leptin in the vascular remodeling associated with obesity.

Authors:  E Martínez-Martínez; M Miana; R Jurado-López; M V Bartolomé; F V Souza Neto; M Salaices; N López-Andrés; V Cachofeiro
Journal:  Int J Obes (Lond)       Date:  2014-03-03       Impact factor: 5.095

8.  Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.

Authors:  Jonathan Beaudoin; Jagmeet P Singh; Jackie Szymonifka; Qing Zhou; Robert A Levine; James L Januzzi; Quynh A Truong
Journal:  Can J Cardiol       Date:  2016-06-02       Impact factor: 5.223

9.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study.

Authors:  Luc Djoussé; Chisa Matsumoto; Andrew Petrone; Natalie L Weir; Michael Y Tsai; J Michael Gaziano
Journal:  Eur J Heart Fail       Date:  2013-12-04       Impact factor: 15.534

10.  Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.

Authors:  Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola
Journal:  J Card Fail       Date:  2015-11-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.